Woods M L, MacGinley R, Eisen D P, Allworth A M
Infectious Diseases Unit, Wattlebrae, Royal Brisbane Hospital, Herston, Queensland, Australia.
AIDS. 1998 Aug 20;12(12):1491-4. doi: 10.1097/00002030-199812000-00011.
To describe two cases of cryptococcal meningitis and one re-exacerbation of Cryptococcus-associated meningitis occurring in temporal association with commencement of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection (CD4 cells < 50 x 10(6)/l), which suggests that partial immune restitution can facilitate development of clinically apparent meningitis in response to Cryptococcus or its antigen.
All HIV-infected patients with culture-proven cryptococcal meningitis diagnosed at a tertiary referral centre specialist infectious diseases unit from 1 January 1996 to 31 December 1996 were reviewed to examine the clinical and immunological parameters prior to and after commencing antiretroviral therapy.
Three patients were diagnosed with clinically apparent meningitis within 7-39 days of changing or altering antiretroviral combination therapy consisting of zidovudine or stavudine, in combination with lamivudine and saquinavir. All patients had CD4 cell counts below 50 x 10(6)/l at initiation of therapy. Following institution of HAART, evidence of immune restitution was suggested by the following: (i) significant increases (3.7-14-fold) in numbers of CD4 cells (all three patients), (ii) significantly reduced (> 2-4 log10 reduction) HIV viral loads (two out of three patients), and (iii) prominent inflammatory changes in cerebrospinal fluid (white blood cells > 10 x 10(6)/l) at diagnosis (two out of three patients).
Our report suggests that in patients with advanced HIV infection, partial immune restitution induced by HAART can precipitate onset of clinically apparent meningitis in those patients with latent cryptococcal central nervous system infection or with residual cryptococcal antigen present in the cerebrospinal fluid.
描述两例隐球菌性脑膜炎病例以及一例隐球菌相关性脑膜炎再发加重病例,这些病例与晚期HIV感染(CD4细胞<50×10⁶/l)患者开始高效抗逆转录病毒治疗(HAART)在时间上相关联,这表明部分免疫恢复可促使对隐球菌或其抗原产生临床上明显的脑膜炎。
对1996年1月1日至1996年12月31日在一家三级转诊中心的专科传染病科室诊断为经培养证实的隐球菌性脑膜炎的所有HIV感染患者进行回顾,以检查开始抗逆转录病毒治疗前后的临床和免疫学参数。
3例患者在改变或调整由齐多夫定或司他夫定联合拉米夫定和沙奎那韦组成的抗逆转录病毒联合治疗后的7 - 39天内被诊断为临床上明显的脑膜炎。所有患者在治疗开始时CD4细胞计数均低于50×10⁶/l。在开始HAART后,有以下证据提示免疫恢复:(i)CD4细胞数量显著增加(3.7 - 14倍)(所有3例患者),(ii)HIV病毒载量显著降低(>2 - 4 log₁₀降低)(3例患者中的2例),以及(iii)诊断时脑脊液中有明显的炎症变化(白细胞>10×10⁶/l)(3例患者中的2例)。
我们的报告表明,在晚期HIV感染患者中,HAART诱导的部分免疫恢复可促使那些有潜伏性隐球菌中枢神经系统感染或脑脊液中存在残留隐球菌抗原的患者发生临床上明显的脑膜炎。